LUCEMYRA PRIOR AUTHORIZATION REQUEST FORM



OptumRx
P.O. Box 25184
Santa Ana, CA, 92799
Phone: (800) 310-6826 Fax: (866) 940-7328





		Community Plan	
Today's Date		-	
Note: This form must be completed by the prescribin	na nrovider		
		una d**	
**All sections must be complete Patient's	Date of Birth /	rnea	
Medicaid # LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLL	Prescriber's Name		
Name	Prescriber's Name		
Prescriber's IN License #	Specialty		
Prescriber's NPI #	Prescriber's Signature		
Return Fax #	Return Phone #		
Check box if requesting retro-active PA	Date(s) of service requested for retro-active eligibility (if applicable):		
	г		
Requested Medication Quantity	Dosage Regimen	Treatment Duration	
Requested Medication Quantity	Dosage Regimen	Treatment Duration	
*Note: Requested dose may not exceed 16 tablets (2.88 mg			
*Note: Requested dose may not exceed 16 tablets (2.88 mg treatment course every 180 days	g) per day; duration may not ex		
*Note: Requested dose may not exceed 16 tablets (2.88 mg treatment course every 180 days	g) per day; duration may not ex		
*Note: Requested dose may not exceed 16 tablets (2.88 mg treatment course every 180 days PA requirements for LUCEMYRA (LOFEXIDI	g) per day; duration may not ex	cceed 14 days, for 1	
*Note: Requested dose may not exceed 16 tablets (2.88 mg treatment course every 180 days PA requirements for LUCEMYRA (LOFEXIDI	g) per day; duration may not ex NE) d alpha-2 adrenergic agonis	cceed 14 days, for 1	
*Note: Requested dose may not exceed 16 tablets (2.88 mg treatment course every 180 days PA requirements for LUCEMYRA (LOFEXIDII 1. Previous trial and failure of a guideline-accepted lifyes, name of previous alpha-2 adrenergic ago	g) per day; duration may not ex NE) d alpha-2 adrenergic agonis onist agent(s) and dose(s) tr	et agent	
*Note: Requested dose may not exceed 16 tablets (2.88 mg treatment course every 180 days PA requirements for LUCEMYRA (LOFEXIDII) 1. Previous trial and failure of a guideline-accepted	g) per day; duration may not ex NE) d alpha-2 adrenergic agonis onist agent(s) and dose(s) tr	et agent	
*Note: Requested dose may not exceed 16 tablets (2.88 mg treatment course every 180 days PA requirements for LUCEMYRA (LOFEXIDII 1. Previous trial and failure of a guideline-accepted lifyes, name of previous alpha-2 adrenergic ago	g) per day; duration may not ex NE) d alpha-2 adrenergic agonis onist agent(s) and dose(s) tr	et agent Yes No	
*Note: Requested dose may not exceed 16 tablets (2.88 metreatment course every 180 days PA requirements for LUCEMYRA (LOFEXIDIDATE of a guideline-accepted liftyes, name of previous alpha-2 adrenergic ago Note: confirmation of previous trial by claims history of the state of t	g) per day; duration may not ex NE) d alpha-2 adrenergic agonis onist agent(s) and dose(s) tr	et agent Yes No	
*Note: Requested dose may not exceed 16 tablets (2.88 metreatment course every 180 days PA requirements for LUCEMYRA (LOFEXIDIDATE of a guideline-accepted liftyes, name of previous alpha-2 adrenergic ago Note: confirmation of previous trial by claims history of the state of t	g) per day; duration may not ex NE) d alpha-2 adrenergic agonis onist agent(s) and dose(s) tr	et agent Yes No	
*Note: Requested dose may not exceed 16 tablets (2.88 metreatment course every 180 days PA requirements for LUCEMYRA (LOFEXIDIDATE of a guideline-accepted liftyes, name of previous alpha-2 adrenergic ago Note: confirmation of previous trial by claims history of the state of t	g) per day; duration may not expense. NE) d alpha-2 adrenergic agonise onist agent(s) and dose(s) tree resubmitted chart documentation are over other alpha-2 adreners.	st agent Yes No rialed: on is required ergic agonist agents:	

07.01.2023 Page 1

3.	Requested claim is within the plan limitation maximum of 7-day supply with a subsequent claim(s) not to exceed 7-day supply (for a total of 14 days of therapy) every 180 days? \square Yes \square No		
	If no, please provide medical rationale for continued use beyond 14 days:		
1			

CONFIDENTIAL INFORMATION

This facsimile transmission (and attachments) may contain protected health information from the Indiana Health Coverage Programs (IHCP), which is intended only for the use of the individual or entity named in this transmission sheet. Any unintended recipient is hereby notified that the information is privileged and confidential, and any use, disclosure, or reproduction of this information is prohibited

07.01.2023 Page 2